Publication

Development of cyclic peptides that can be administered orally to inhibit disease targets

Related publications (22)

About
Privacy
Disclaimer

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Development of cyclic peptides that can be administered orally to inhibit disease targets

Graph Chatbot

Chat with Graph Search

Methods for high-throughput synthesis and screening of peptide libraries

Solid-phase peptide synthesis in 384-well plates

Development of methods for the synthesis of large combinatorial libraries of macrocyclic compounds

Synthesis and application of bifunctional hypervalent iodine reagents for peptide modification.

De novo developed small cyclic peptides that are orally available

Solid-phase peptide synthesis on disulfide-linker resin followed by reductive release affords pure thiol-functionalized peptides

Methods for the generation of large combinatorial macrocycle libraries

De novo development of proteolytically resistant therapeutic peptides for oral administration

Discovery of novel competitive dihydropteridine reductase inhibitors via high throughput screening and their effect on metabolic pterin balance of fibroblast.

Development of cyclic peptide inhibitors of coagulation factor XII and matrix metalloproteinase 2